Natalizumab treatment is associated with improved patient-reported outcomes in the treatment of multiple sclerosis: results from a systematic literature review

Grants

Funding Acknowledgements

K Nair received personal compensation for consulting from Astellas and grant funding from Biogen, Genentech, Novartis and Gilead. T Vollmer received honoraria for serving on scientific advisory boards, lectures and for consulting services from AbbVie Inc, Aclimed, American Academy of Neurology, CB Partners, Capmaels and Rasford, Celestial Intas Pharmaceuticals Ltd, Compass Learning, Genentech/Roche, Genzyme/Sanofi, Goodwin Procter LLP, IMS Consulting Group, Medscape, Novartis Pharmaceuticals, Oxford Pharmagenesis, Patient Centered Outcomes Research Institute, Sommer Consulting, and Teva Neuroscience as well as research support from Genzyme, Teva Neuroscience, NIH/NINDS, Rocky Mountain MS Center, EMD Serono, Biogen Idec, Ono Pharmaceuticals, Medimmune and TG Therapeutics Inc. K Lipman is an employee of ICON, which was commissioned to conduct the research. E Flood is an employee of ICON, which was commissioned to conduct the research. C Davey is an employee of ICON, which was commissioned to conduct the research. W Huang is an employee of University of California San Francisco and is conducting a fellowship at Biogen. M Jhaveri is an employee of, and holds stock/stock options in Biogen. L Lee is an employee of, and holds stock/stock options in Biogen. S Licata is an employee of, and holds stock/stock options in Biogen. S Naoshy is an employee of, and holds stock/stock options in Biogen.